Poad, H.; Khan, S.; Wheaton, L.; Thomas, A.; Sweeting, M.; Bujkiewicz, S.
The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status. Cancers 2022, 14, 5391.
https://doi.org/10.3390/cancers14215391
AMA Style
Poad H, Khan S, Wheaton L, Thomas A, Sweeting M, Bujkiewicz S.
The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status. Cancers. 2022; 14(21):5391.
https://doi.org/10.3390/cancers14215391
Chicago/Turabian Style
Poad, Heather, Sam Khan, Lorna Wheaton, Anne Thomas, Michael Sweeting, and Sylwia Bujkiewicz.
2022. "The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status" Cancers 14, no. 21: 5391.
https://doi.org/10.3390/cancers14215391
APA Style
Poad, H., Khan, S., Wheaton, L., Thomas, A., Sweeting, M., & Bujkiewicz, S.
(2022). The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status. Cancers, 14(21), 5391.
https://doi.org/10.3390/cancers14215391